, /PRNewswire/ -- The global size is estimated to grow by billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.9% during the forecast period.
For more insights on the forecast market size and historic data (2018 - 2022) - Immunomodulatory therapies are pivotal in treating various medical conditions like autoimmune diseases, inflammation, infections, cancer, and organ transplants. In ARDS management, they complement standard treatments such as lung-protective ventilation and supportive care. Pharmaceutical companies, biotech firms, and academic institutions are actively researching new immunomodulatory agents for ARDS.
These include anti-inflammatory drugs, cytokine inhibitors, corticosteroids, and biologics. Clinical trials are underway to assess their safety and efficacy, often in combination with standard treatments. Advances in immunology and molecular biology have revealed new therapeutic targets and pathways in ARDS.
Immunomodulatory therapies target molecules like interleukin-1, interleukin-6, tumor necrosis factor-alpha, chemokines, adhesion molecules, and immune cell receptors to modulate immune responses and reduce lung injury in ARDS. The increasing interest in immunomodulatory therapies is expected to drive growth in the global ARDS treatment market. Research report provides comprehensive data on impact of trend, driver and challenges - During the projected period, hospital pharmacies are expected to capture a notable porti.
